论文部分内容阅读
[目的]用放射性碘Na~(131)I标记热休克蛋白90α单克隆抗体,研究其在胶质瘤荷瘤小鼠模型的生物分布以及放射免疫治疗效果。[方法]热休克蛋白90α单克隆抗体的放射性~(131)I标记采用氯胺T法进行。标记抗体经尾静脉注射到U87细胞荷瘤小鼠模型体内,在注射体内后6、12、24h处死小鼠,测量其在各组织器官内的分布。放免实验分为实验组、对照组和未标记组,每组6只小鼠,注射药物后每5天测量肿瘤体积,连续40天。并记录全部小鼠注射后的生存时间。[结果]热休克蛋白90α单克隆抗体标记效率达到56%,纯化后放射化学纯度超过95%。分布数据表明~(131)I-Hsp90α单克隆抗体主要累积在肝脏、脾脏和肿瘤。治疗组肿瘤体积明显小于其他两组,抑瘤率高于其余两组且生存时间更长。[结论]热休克蛋白90α单克隆抗体可以用氯胺T法成功标记~(131)I。~(131)I标记热休克蛋白90α单克隆抗体可以被U87荷瘤小鼠的肿瘤组织特异性摄取,其用于放免治疗有一定的研究价值和临床应用前景。
[Objective] To study the biodistribution and radioimmunotherapy of heat shock protein 90α monoclonal antibody in Naïve (131) I-bearing mice. [Method] Radioactive 131I labeling of heat shock protein 90α monoclonal antibody was performed by chloramine T method. The labeled antibody was injected into the U87 cell tumor-bearing mouse model via caudal vein, and the mice were sacrificed at 6, 12 and 24 h after injection. The distribution of the labeled antibody in each tissue and organ was measured. Radiation-free experiments were divided into experimental group, control group and unlabeled group, 6 mice in each group. The tumor volume was measured every 5 days after injection of drug for 40 consecutive days. All mice were recorded for survival time after injection. [Result] The labeling efficiency of heat shock protein 90α monoclonal antibody reached 56% and the radiochemical purity exceeded 95% after purification. Distribution data show that ~ (131) I-Hsp90α monoclonal antibody mainly accumulates in liver, spleen and tumor. The tumor volume in the treatment group was significantly smaller than that in the other two groups, and the tumor inhibition rate was higher than the other two groups and the survival time was longer. [Conclusion] The monoclonal antibody of heat shock protein 90α can successfully label ~ (131) I with chloramine T method. The ~ (131) I-labeled HSP90a monoclonal antibody can be specifically upregulated by the tumor tissue of U87 tumor-bearing mice, and it has certain research value and clinical application prospect for radioimmunotherapy.